创新药到底经历了什么，后面还有没有行情？

Core Viewpoint - The innovative drug sector has reached a stage where it is largely ignored by the market, despite positive changes in company fundamentals and a significant increase in the number of licensing deals [3][4][5]. Group 1: Historical Context of the Innovative Drug Sector - The current market cycle for innovative drugs has transitioned from a period of significant valuation decline to a recovery phase, with many companies' valuations hitting historical lows [6][7]. - A clear turning point in fundamentals was observed in early 2025, with a shift from a model reliant on continuous funding for R&D to one focused on revenue generation from product sales and improved cash flow [7]. - The number of licensing deals in China surged to approximately 157, with a total value exceeding $130 billion, more than doubling from the previous year, indicating a strong presence in the global business development market [7][8]. Group 2: Recent Market Adjustments - From September 2025 to February 2026, many companies experienced a market correction of around 30%, primarily driven by funding issues and external market conditions rather than fundamental industry problems [9][10]. - The disconnect between industry progress and stock price performance is evident, with the sector experiencing a typical "good industry + temporary negative sentiment" scenario [11]. Group 3: Comparison with Previous Market Cycles - The current phase (2025 onwards) differs significantly from the previous cycle (2018-2020), which was characterized by domestic institutional benefits and valuation discovery, with many companies still in early clinical stages [12][13]. - In contrast, the current cycle features companies that have advanced to leading positions in certain therapeutic areas, with a notable increase in the global market share of Chinese innovative drugs [13][14]. Group 4: Future Outlook for 2026 - The year 2026 is anticipated to be pivotal, with a shift from speculative valuations to a focus on actual data and cash flow, as companies like BeiGene are expected to achieve significant profitability [15][16]. - Key clinical milestones for several major drugs are expected in 2026, which will serve as critical tests for their global market potential [17][18]. Group 5: Market Trends and Opportunities - The global innovative drug market is projected to grow at a compound annual growth rate (CAGR) approaching double digits, potentially exceeding $1 trillion by 2030, with the Chinese market expected to reach approximately $100 billion by 2025 [21][22]. - The role of Chinese innovative drugs in the global supply chain is evolving from a passive participant to a significant contributor, with increasing procurement from multinational pharmaceutical companies [22][23]. Group 6: Catalysts for Market Recovery - The market is currently in a phase of adjustment, with a need for a catalyst to realign value perceptions, which could come from significant clinical data releases at major conferences or a shift in investor focus back to innovative drugs [24][25]. - The emergence of a landmark drug achieving global market entry and pricing could significantly uplift the sector's overall valuation [26].